-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: VK-2735...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2735 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Obesity Drug Details: VK-2735 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2809 in Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2809 in Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2809 in Fibrosis Drug Details: VK-2809 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: VK-2809...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Idiopathic Pulmonary Fibrosis Drug Details: AD-214 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-0612 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-0612 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-0612 in Type 2 Diabetes Drug Details: VK-0612 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: VK-2809 is...
-
Product Insights
NewMuscle Wasting Disorders – Drugs In Development, 2024
Empower your strategies with our Muscle Wasting Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Muscle wasting is evident in diverse pathologies like cancer, chronic kidney disease, heart failure, chronic obstructive pulmonary disease (COPD), and during aging or extended inactivity. Diminished muscle mass and function correlate with increased morbidity and mortality, along with a diminished quality of life. Elevated levels of pro-inflammatory cytokines are frequently observed in the plasma of individuals experiencing muscle wasting conditions, prompting...